Effect of Interferon Therapy on the Natural History of Hepatitis C Virus-Related Cirrhosis and Hepatocellular Carcinoma

Poynard, Thierry; Moussalli, J.; Ratziu, Vlad; Regimbeau, C.; Opolon, P

doi:10.1016/s1089-3261(05)70244-0

Cited by 42 publications

(33 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Given the many reports of the efficacy of IFN-based therapy in ameliorating hepatic inflammation, fibrosis, and serum alanine aminotransferase levels and in decreasing circulating HCV-RNA levels and the risk of HCC [9][10][11][12][13][14], we speculated that IFN treatment and HCV eradication would be an effective cancer chemoprevention strategy for patients with chronic hepatitis C. Supporting this, one study estimated 7-year cumulative incidence rates of HCC in sustained responders, transient responders, and nonresponders of 4.3, 4.7, and 26.1%, respectively [9], while several others have reported that the decrease in incidence of HCC with IFN treatment is particularly clear among patients with a sustained virological response (SVR) [10,11,[15][16][17]. In contrast, however, others have reported the development of HCC in patients with SVR [18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

et al. 2011

View full text Add to dashboard Cite

We found that, despite HCV eradication, patients with the risk factors of high age at HCV eradication and heavy alcohol intake might be at heightened risk for the development of HCC within 5 years after HCV eradication. In contrast, risk factors for the development of HCC more than 10 years after HCV eradication were uncertain. These findings indicate the need for long-term surveillance for HCC after HCV eradication.

show abstract

Section: Introductionmentioning

confidence: 99%

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Valla et al [5] found no beneficial effect on the development of decompensation or HCC, whereas Poynard et al [6] suggested that IFN therapy could reduce the incidence of and mortality from HCC. In 2000, Heathcote et al [7] showed in patients with cirrhosis that pegylated (PEG)-IFN once weekly was more effective for achieving a sustained virological response (SVR) compared with standard IFN (43 vs. 15%).…”

Section: Interferon-ribavirin Combination In Patients With Hcv-inducementioning

confidence: 99%

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis

Bailly

Pradat²,

Virlogeux³

et al. 2015

Dig Dis

View full text Add to dashboard Cite

Background: Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon (IFN)-α monotherapy in the early 1990s to the approval of telaprevir- and boceprevir-based triple therapies with pegylated (PEG)-IFN-α and ribavirin (RBV) in 2011, the chances of curing patients infected with HCV genotype 1 have improved dramatically to reach approximately 70%. Significant further improvements that may cure virtually all HCV patients with an all-oral, IFN-free regimen are becoming progressively available. Key Messages: Historically, a PEG-IFN/RBV combination therapy of patients with liver cirrhosis was associated with lower virological rates and a worse safety profile. The advent of the first protease inhibitor-based triple therapy was long expected, but the promise fell rapidly because of the numerous side effects and the requirement for intensive clinical management in cirrhotic patients. The newer direct-acting antivirals (DAAs) target the viral polymerase with either nucleos(t)ide analogues or nonnucleosidic inhibitors, the viral protease and the viral NS5A protein. Several clinical trials have now shown that a combination of sofosbuvir (nucleosidic polymerase inhibitor) with daclatasvir or ledipasvir (NS5A inhibitors), or sofosbuvir with simeprevir (protease inhibitor), or a combination of ABT-450 (protease inhibitor) with ritonavir (ABT-450/r), the nonnucleosidic polymerase inhibitor ABT-333 and the NS5A inhibitor ABT-267, can achieve a sustained virological response in up to 95% of naive patients or previously treated patients, even in those who failed prior treatment with first-generation protease inhibitors. The best treatment regimens enable the achievement of comparable results even in cirrhotics, while other regimens still require RBV or a longer treatment duration to achieve optimal results. This improved risk/benefit ratio justifies early access programs of IFN-free regimens for cirrhotic patients. The remaining difficult-to-treat patients are cirrhotics infected with HCV genotype 3 and those with decompensated cirrhosis, for whom novel DAA combinations should be evaluated in clinical trials. Conclusions: As new DAAs are becoming available in early access treatment programs, treatment strategy studies are being performed to optimize treatment regimens with respect to the choice of DAAs and treatment duration, based on viral genotypes, prior treatment response and the presence of liver cirrhosis. In the near future, this should allow: (i) a decrease in the complications of HCV-induced cirrhosis, (ii) liver transplantations to be performed in virally cured patients, and (iii) the rescue of patients in the worst clinical situation (decompensated cirrhosis and HCV recurrence on liver graft).

show abstract

“…En effet, même si le risque de carcinome hépatocellulaire est beaucoup plus important en cas de maladie active (3 à 5 % par an au stade de cirrhose), ce risque persiste en cas de cirrhose éteinte (23)(24)(25). Une régression de la cirrhose est maintenant admise mais si celle-ci est déjà évoluée, cette hypothèse reste plus incertaine.…”

Section: Comment Suivre Un Patient Après « Guérison Virologique » ?unclassified

XXVIIIe congrès du CREGG, 25–26 septembre 2009, Marne-la-Vallée

2009

Acta Endosc

View full text Add to dashboard Cite

Effect of Interferon Therapy on the Natural History of Hepatitis C Virus-Related Cirrhosis and Hepatocellular Carcinoma

Cited by 42 publications

References 37 publications

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

Clinical features and prognosis in patients with hepatocellular carcinoma that developed after hepatitis C virus eradication with interferon therapy

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis

XXVIIIe congrès du CREGG, 25–26 septembre 2009, Marne-la-Vallée

Contact Info

Product

Resources

About